key: cord-0323298-tk0iwpnb
authors: Dolzhikova, I.; Gushchin, V.; Shcheblyakov, D.; Tsybin, A.; Shchetinin, A.; Pochtovyi, A.; Komissarov, A.; Kleymenov, D.; Kuznetsova, N.; Tukhvatulin, A.; Zubkova, O.; Dzharullaeva, A.; Kovyrshina, A.; Lubenets, N.; Grousova, D.; Erokhova, A.; Izhaeva, F.; Popova, O.; Ozharovskaya, T.; Semikhin, A.; Tokarskaya, E.; Shmarov, M.; Nikitenko, N.; Shidlovskaya, E. V.; Bykonia, E.; Mazunina, E.; Divisenko, E.; Vasilchenko, L.; Popova, L.; Danilenko, D.; Lioznov, D.; Tkachuk, A.; Borisevich, S.; Naroditsky, B.; Logunov, D.; Gintsburg, A.
title: One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
date: 2021-10-14
journal: nan
DOI: 10.1101/2021.10.08.21264715
sha: 0f98bc2c1e87bc0776753ab608aec751488faec4
doc_id: 323298
cord_uid: tk0iwpnb

Objectives Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow. Methods To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021. Results Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group - 75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines. Conclusion The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people (86.2% and 75.28%, respectively), at least during the first 3 months after receiving the one-shot vaccine.

Vaccination remains the most effective response to the COVID-19 pandemic. Most vaccines use two-dose regimens. In turn, single-dose vaccines also have high potential, since, on the one hand, they simplify the vaccination program, make it more accessible and convenient for more people around the world, and on the other hand, they are better suited for subsequent revaccination. However, there is not enough data on the effectiveness of single-dose vaccine variants against new genetic lines to assess their current potential. It is not clear how much a single dose of immunization protects against the globally dominant delta variant. In this work, we investigated the effectiveness of a single dose vaccine (Sputnik Light, the first component of Sputnik V vaccine) against the Delta variant in Moscow.

To assess the effectiveness of one dose of viral vector vaccine based on rAd26 against the delta variant in Moscow, we used data from the Moscow registries of vaccination against COVID-19 and the incidence of COVID-19. The availability of data on the number of seropositive residents of Moscow made it possible to consider the size of the immune layer formed because of a previous COVID-19 disease or vaccination. To calculate the effectiveness, the proportion of COVID-19 cases among those vaccinated with a single dose and the proportion of cases among those who were not vaccinated in July 2021.

Our data indicate that throughout July 2021, the dominant variant of the coronavirus at the level of 99.5% in Moscow was the SARS-CoV-2 delta variant and its subsidiary lines. Considering the immune layer of 46% allowed us to calculate the effectiveness of a one-shot vaccine against the delta variant in Moscow during the first three months after vaccination at the level of 69.85% (95% confidence interval [CI], 64.08 to 74.70). In the 18-29-year-old group, the overall vaccine efficacy against the delta variant was 88.61%, in the 18-59 group -75.28%. Sputnik Light demonstrates higher efficacy against Delta variant than many two-shot vaccines.

The results indicate a high efficacy of a single immunization first component of Sputnik V vaccine against delta variant among young and middle-aged people, at least during the first 3 months after receiving the one-shot vaccine.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

Today, there is a fairly large selection of vaccines for the prevention of COVID-19, which have shown high efficiency at the stage of clinical trials. [1] [2] [3] [4] . However, the efficacy against the SARS-CoV-2 delta variant for many vaccines has decreased [5] [6] , which explains the increase in the global incidence of COVID-19 even against the high percentage of vaccinated in developed countries [7] .

Genetic line B.1.617.2 delta was first identified in samples from patients from India [8] .

This genetic line has the status of a variant of concern (VOC-21APR-02) and has a few key mutations in the S protein, including: T19R G142D E156G F157del R158del L452R T478K D614G P681R D950N. A new set of RBD mutations of the delta variant significantly reduces the virus neutralizing properties of antibodies formed by vaccination or a previous disease, promotes the formation of syncytia, allowing additional escape from antibody protection [9] . V vaccine, heterologous prime-boost immunization regimen is used when two different rAd serotypes are used: rAd26 and rAd5 [11] . In turn, the Sputnik Light vaccine is a one-shot vaccine -the first component based on rAd 26 [12] . The protective efficacy of the Sputnik V vaccine, according to the third phase of clinical trials conducted on the territory of the Russian Federation, was 91.6% [4] . Available data from studies of the effectiveness of two doses of vaccination with Sputnik V indicate that the vaccine against the delta variant is above 80% [13] [14] . Data on COVID-19 cases in June 2021 shows that the effectiveness of the Sputnik V vaccine against the delta variant is about 83% [15] .

It is important to understand how effective a single vaccination is. Given that the singledose vaccine has many advantages, including a simplified vaccination program that makes it more accessible and convenient for more people around the world, there is an urgent need to obtain data on the effectiveness of the first component of Sputnik V specifically in relation to SARS-CoV-2 delta variant. In this study, we performed a preliminary calculation of the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint effectiveness of a single immunization with first component of Sputnik V against delta according to the Moscow vaccination registries and the incidence of COVID-19.

According to the Russian consortium for coronavirus genome sequencing -CORGI (https://corgi.center/en/) in June 2021, the frequency of the genetic line delta B.1.617.2 and its descendant lines in Russia was more than 90%, while in July 2021 it exceeded 98.5% [16] . We Table S1 ). It should be noted that it apparently took no more than perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in We obtained data from registries of COVID-19 cases and vaccinated persons, as well as data on the number of Moscow residents in different age cohorts. Among those vaccinated with a single dose, the number of those who received the first dose of the vaccine in the interval from 21 days to 3 months after vaccination at the beginning of July and the number of cases among them during July were taken into account. In the case of non-immune people, the number of people not included in the immune layer (who did not receive any of the available vaccines, did not get sick, did not have specific antibodies at the beginning of July, ~ 54% of the Moscow population) and the number of people who were sick among them were taken into account. The effectiveness of the vaccine was calculated in relation to the odds ratio among the group of once vaccinated and the group of non-immune, according to the WHO

We found that the overall efficacy of single-dose vaccination against the delta variant was 69.85% (table 1, figure 2 ). In the group of 18-29 yo, the effectiveness for the vaccine was 88.61%, in the group 18-59 yo -75.28%, while with age, the effectiveness of the vaccine tended to decrease and in the group over 60 it was 51.98% (table 1, figure 2). [18] [19] . It will take at least several months to confirm that the new vaccines are safe and more effective against the delta variant than the older vaccines. However, the decline in efficacy of the available vaccines may not be the same.

Thus, there is reason to believe that the decrease in immunity over time in relation to the delta variant for the Astrazeneca drug may be less than for the Pfizer/BNT drug [20] . The difference in the dynamics of maintaining efficiency can be associated with both the characteristics of the All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Here we made a calculations of the effectiveness of first component of Sputnik V vaccine using data from the Moscow registries of morbidity and vaccination against COVID-19. To calculate the efficiency, July 2021 was selected for which the total share of the delta B.1.617.2 variant and its descendants (advantage AY.12) was 99.5%. We calculated the size of a group that did not have preexisting immunity using a 54% non-immune rate, which was estimated thanks to constant serological monitoring carried out in Moscow. Our data indicate that the overall efficacy of a single-dose vaccine against the delta variant is 69.85% (95% CI, 64.08-74.70). This is significantly higher than for BNT162b2 and ChAdOx1 nCoV-19, for which the efficacy of a single dose against delta was estimated at 35.6% (22.7-46.4) and 30.0% (24.3-35. 3), respectively [6] . Direct comparisons are difficult to make due to differences in study design. In the first case, a test-negative case-control design was used against the use in our case of an assessment based on the total upload of all data from the Moscow vaccination and morbidity registers with an adjustment for the size of the immune layer and calculation of the odds ratio (OR). Also, a significant difference may be that we took into account the effectiveness only within the first three months after vaccination. Evaluation of effectiveness during the first three months can be attributed to the limitation of our study. The choice of such an interval was caused by the fact that truly mass vaccination in Moscow began in April 2021, All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint when the Moscow authorities began to tighten requirements for vaccination among people working in the service sector. Thus, many partially vaccinated people met dominant delta during summer 2021. Meanwhile, even for immunization with two doses, the revaccination period is set at six months after the primary immunization, so that the assessment of efficacy based on the first three months is an informative assessment.

Our results show that in age cohorts, the efficacy of a single-dose vaccine against the delta variant differs. Among young 18-29 years old, the effectiveness for the vaccine was 88.61% (95% CI, 78.81-93.88), in general among the 18-59 age group -75.28 (95% CI, 69.24-80.13). However, with age, the effectiveness of the vaccine tended to decrease and in the group over 60 it was about 52%. Further studies are needed to determine the conditions for revaccination for patients who received the only one dose of the vaccine in different age cohorts.

The results indicate a high efficacy of a single immunization with an adenovirus vaccine based on rAd26 (first component of Sputnik V vaccine) against SARS-CoV-2 delta variant among young and middle-aged people (18-59 yo) , at least during the first 3 months after receiving the vaccine.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

We conducted an observational study of vaccine efficacy by screening method. In order to analyze the vaccine efficacy, it was necessary to select the right group of comparison. The Odds ratio (OR) and limits of 95% confidence interval of the odds ratio were calculated according to Tenny and Hoffman [25] , p values were obtained by χ2 test or Fisher's exact test.

The statistical analysis was done using Microsoft Excel, and GraphPad Prism v. 9.2.

The samples used in this study were collected as part of the ongoing surveillance of viral variability routinely conducted at the Gamaleya Center. Written informed consent was obtained from all subjects in accordance with the order of the Ministry of Health of the Russian All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint Federation of July 21, 2015 N 474n. All samples were de-identified prior to receipt by the research team. The study was submitted to the Local Ethics Committee of the Gamaleya Center.

The committee concluded that the study did not use identifiable biological samples and did not provide any confidential data. Consequently, according to the Local Ethics Committee rules and national regulations, this project does not require ethical approval.

Total RNA was extracted from patient's nasopharyngeal swab's and whole-genome amplification of SARS-CoV-2 virus genome was performed using ARTIC Network protocol as described previously [26] [27] . Analysis of SARS-CoV-2 genetic diversity in Russia using GISAID was performed as described previously [28] .

IVD, DVS, AIT, OVZ, ASD, DMG, ASE, OP, TAO, ASS, EAT, NAN, SVB, BSN, DYL and ALG report patents for a Sputnik V immunobiological expression vector, pharmaceutical agent, and its method of use to prevent COVID-19. All other authors declare no competing interests.

We would like to thank all the colleagues and all vaccinated people who took part in this study.

The study was funded by Ministry of Health of Russia, Moscow Healthcare Department and Russian Direct Investment Fund. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint

SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK

Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia

Impact of the Delta variant on vaccine efficacy and response strategies

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

An Interactive Web-Based Dashboard to Track COVID-19 in Real Time

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains. Sci Rep

Safety and Immunogenicity of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies from Russia. The Lancet

Vaccine for Prevention of Coronavirus Infection in Healthy Adults

Vaccine Effectiveness against Referral to Hospital and Severe Lung Injury Associated with COVID-19: A Population-based Casecontrol Study in St

Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain

Russia's Sputnik V shot around 83% effective against Delta variant, health minister says

Evaluation of COVID-19 vaccine effectiveness

Pfizer says it is developing a Covid booster shot to target the highly transmissible delta variant PUBLISHED THU, JUL 8 2021 5:03 PM EDT, UPDATED TUE, JUL 13 20216:45 PM EDT

2021) 20. Financial Times. Are vaccines becoming less effective at preventing Covid infection?

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

mRNA vaccines against COVID-19: Pfizer

BioNTech COVID-19 vaccine BNT162b2: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines

Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity

Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina

Odds Ratio

Genomic epidemiology of the early stages of the SARS-CoV-2 outbreak in Russia

Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines (Basel)

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.08.21264715 doi: medRxiv preprint